Quarterly Result29 May 2026, 09:38 pm
Kabra Drugs Ltd: FY26 Net Loss After Tax ₹108.56 Lakhs
AI Summary
Kabra Drugs Ltd's board meeting on May 29, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The company reported a total income of ₹3,551.91 lakhs for the quarter ended March 31, 2026, and ₹9,323.27 lakhs for the financial year ended March 31, 2026. The net loss after tax for the year stood at ₹108.56 lakhs. The board confirmed that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable as the company has not issued shares via public, right, or preferential issues.
Key Highlights
- Kabra Drugs approved audited financial statements for FY26.
- Total income for FY26 reached ₹9,323.27 lakhs.
- Net loss after tax for FY26 was ₹108.56 lakhs.
- Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company.
- Board meeting commenced at 05:00 p.m. (IST) and concluded at 06:30 p.m. (IST).